Hyperparathyroidism Following Denosumab and Zoledronate Therapy in a Secondary Care Setting

J Clin Rheumatol. 2023 Mar 1;29(2):101-104. doi: 10.1097/RHU.0000000000001894. Epub 2022 Aug 18.

Authors

Jalpa Kotecha¹, Kazi Mashfia Fardeen², Mehdi Mirzazadeh²

Affiliations

¹ From the King's College Hospital, London.
² St Helier Hospital, Carshalton, England.

PMID: 35981297
DOI: 10.1097/RHU.0000000000001894

No abstract available

MeSH terms

Bone Density
Bone Density Conservation Agents*
Denosumab
Humans
Hyperparathyroidism*
Secondary Care
Zoledronic Acid

Substances

Zoledronic Acid
Denosumab
Bone Density Conservation Agents